Efficacy of a novel pancreatic enzyme product, EUR-1008 (Zenpep), in patients with exocrine pancreatic insufficiency due to chronic pancreatitis

Pancreas

Volumn 40, Issue 3, 2011, Pages 376-382

  Toskes, Phillip P ^a   Secci, Angelo ^b   Thieroff Ekerdt, Ruth ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Eurand Pharmaceuticals Inc   (United States)

Author keywords

chronic pancreatitis; coefficient of fat absorption; crossover trial; exocrine insufficiency; pancreatic enzyme replacement therapy

Indexed keywords

ERU 1008; NITROGEN; PANCREAS ENZYME; PANCRELIPASE; PLACEBO; UNCLASSIFIED DRUG; ZENPEP;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CHRONIC PANCREATITIS; COEFFICIENT FAT ABSORPTION; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FAT CONTENT; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPESTHESIA; LIPID ABSORPTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NITROGEN METABOLISM; PANCREAS EXOCRINE INSUFFICIENCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXOCRINE PANCREATIC INSUFFICIENCY; FECES; FEMALE; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; PANCREATITIS, CHRONIC; PANCRELIPASE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79954421251     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31820b971c     Document Type: Article

References (11)

1. Spanier BW, Dijkgraaf MG, Bruno MJ. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: an update. Best Pract Res Clin Gastroenterol. 2008;22(1):45-63.
2. Abdel Aziz AM, Lehman GA. Current treatment options for chronic pancreatitis. Curr Treat Options Gastroenterol. 2007;10(5):355-368. (Pubitemid 47559350)
3. Toskes P. Pancreatic enzyme therapy: Improving nutritional health of patients with exocrine pancreatic insufficiency and steatorrhea. Fed Pract. 2009;26(suppl 2):1-25.
4. Krishnamurty DM, Rabiee A, Jagannath SB, et al. Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis. Ther Clin Risk Manag. 2009;5(3):507-520.
5. Ferrone M, Raimondo M, Scolapio JS. Pancreatic enzyme pharmacotherapy. Pharmacotherapy. 2007;27(6):910-920. (Pubitemid 46849433)
6. Domínguez-Munoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep. 2007;9(2):116-122. (Pubitemid 46647523)
7. Wooldridge JL, Heubi JE, Amaro-Galvez R, et al. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. J Cyst Fibros. 2009;8(6):405-417.
8. Halm U, Löser C, Löhr M, et al. A double-blind, randomized, multicentre, crossover study to prove equivalence of pancreatin minimicrospheres versus microspheres in exocrine pancreatic insufficiency. Aliment Pharmacol Ther. 1999;13(7):951-957. (Pubitemid 29312782)
9. Safdi M, Bekal PK, Martin S, et al. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea; a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. Pancreas. 2006;33(2):156-162. (Pubitemid 44174563)
10. Whitcomb DC, Lehman GA, Vasileva G, et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: a double-blind randomized trial. Am J Gastroenterol. 2010;105(10):2276-2286.
11. Vecht J, Symersky T, Lamers CB, et al. Efficacy of lower than standard doses of pancreatic enzyme supplementation therapy during acid inhibition in patients with pancreatic exocrine insufficiency. J Clin Gastroenterol. 2006;40(8):721-725. (Pubitemid 44350595)